CompletedPhase 4

A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

13 participantsStarted 2006-01

Plain-language summary

The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe asthmatics who have ongoing persistent asthma symptoms despite on moderate to high doses of inhaled corticosteroids (ICS). Associations will be assessed between the types of sputum inflammatory markers and the patient's atopic status and level of asthma control as indicated by the following measures: 1. pulmonary function test (PFT) 2. asthma symptoms based on the Asthma Control Test (ACT)

Who can participate

Age range8 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Moderate to severe allergic asthma, uncontrolled on conventional therapy Exclusion Criteria: * History of systemic illness, currently on other immune modulators like immunotherapy, IVIg * Pregnancy * IgE level \>1300

What they're measuring

Number of Participants With Change in Sputum Markers by End of Study

Timeframe: 32 weeks

Trial details

NCT IDNCT00283504

SponsorChildren's Hospital of The King's Daughters

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-01

Results submitted2018-02-07

View on ClinicalTrials.gov More ALLERGIC ASTHMA trials